Renin inhibition in portal hypertension: Novel indication beyond cardiovascular diseases?

Journal of the Chinese Medical Association

Volumn 75, Issue 11, 2012, Pages 547-548

  Huang, Hui Chun ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALPHA SMOOTH MUSCLE ACTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; RENIN; TRANSFORMING GROWTH FACTOR BETA;

DRUG EFFECT; EDITORIAL; ENZYME INHIBITION; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PROTEIN EXPRESSION; STELLATE CELL;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; FUMARATES; HYPERTENSION, PORTAL; RATS; RENIN;

EID: 84869504324     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2012.08.022     Document Type: Editorial

References (15)

1. Westermann D., Schmieder R., Schultheiss H.P., Tschope C. Renin inhibitors, clinical experience. J Mol Med 2008, 86:691-695.
2. Imanishi T., Tsujioka H., Ikejima H., Kuroi A., Takarada S., Kitabata H., et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008, 52:563-572.
3. Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol 2006, 22:254-262.
4. Wiest R., Shah V., Sessa W.C., Groszmann R.J. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999, 276:G1043-G1051.
5. Gupta T., Toruner M., Chung M., Groszmann R. Endothelial dysfunction in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998, 28:926-931.
6. Shah V., Toruner M., Haddad F., Cadelina G., Papapetropoulos A., Choo K., et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999, 117:1222-1228.
7. Rockey D., Chung J. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998, 114:344-351.
8. Herath C.B., Warner F.J., Lubel J.S., Dean R.G., Jia Z., Lew R.A., et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 2007, 47:387-395.
9. Mosca P., Lee F.Y., Kaumann A., Groszmann R. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am J Physiol 1992, 263:G544-G550.
10. ω-nitro-L-arginine ameliorates portal-systemic shunting in portal hypertensive rats. Gastroenterology 1993, 105:1464-1470.
11. Hsieh Y.C., Chan C.C., Lee K.C., Huang Y.T., Lee F.Y., Yang Y.Y., et al. Aliskiren reduces portal pressure and intrahepatic resistance in biliary cirrhotic rats. J Chin Med Assoc 2012, 75:501-508.
12. Chang C.C., Lee W.S., Huang H.C., Lee F.Y., Wang S.S., Lin H.C., et al. Aliskiren reduces portal pressure in portal hypertensive rats. Eur J Clin Invest 2012, 42:526-533.
13. Chang C.C., Huang H.C., Lee W.S., Wang S.S., Lee F.Y., Lin H.C., et al. Aliskiren reduces portal pressure in cirrhotic rats. Liver Int 2012, 32:692-693.
14. Choi D.E., Jeong J.Y., Lim B.J., Chang Y.K., Na K.R., Shin Y.T., et al. Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice. J Urol 2011, 186:694-701.
15. Hirose A., Ono M., Saibara T., Nozaki Y., Masuda K., Yoshioka A., et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45:1375-1381.